The Patent Finder

Crealta Pharmaceuticals LLC

Also on record
Records under this name other than the patents Crealta Pharmaceuticals LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Crealta Pharmaceuticals LLC

PatentTitleStatus Expires Confidence
US 8,148,123Methods for Lowering Elevated Uric Acid Levels Using Intravenous Injections of Peg-Uricase
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 9,377,454Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,139,399Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,823,727Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,598,767Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,639,927Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,982,670Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 12,188,927Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 7,811,800Variant Form of Urate Oxidase and Use Thereof
Term ended
Term ended Apr 11, 2026 · High confidence
Term endedTerm ended Apr 11, 2026High confidence
US 7,964,381Variant Form of Urate Oxidase and Use Thereof
Term ended
Term ended Apr 11, 2026 · High confidence
Term endedTerm ended Apr 11, 2026High confidence
10 of 38 patents shown.
Pro members see all 38.
Pro members: see all 38 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited